Objective To study the effect of Liraglutide (LRG)on newly diagnosed obese type 2 diabetes mellitus(T2DM).Methods A total of 84 newly diagnosed obese T2DM patients in the Department of Endocrinology of Harbin First Hospital from May 2020 to May 2021 were selected as the research objects.They were divided into control group and observation group by random number table method,with 42 cases in each group.Patients in the control group were treated with metformin,while patients in the observation group were treated with LRG.The body mass index (BMI) and blood glucose levels (fasting blood glucose [FPG],2 h postprandial blood glucose [2 h PG]),fibrocyte growth factor-21 (FGF-21) level,microinflammatory indicators (interleukin-6 [IL-6],tumor necrosis factor-α [TNF-α],serum amyloid A [ASAA]),oxidative stress indicators (propylene glycol [MDA],lipid hydrogen peroxide [LPO],glutathione peroxidase [GSH-Px]) and the occurrence of adverse reactions were compared between the two groups.Results The BMI,FPG and 2 h PG of the observation group after treatment were lower than those of the control group,and the differences were statistically significant(P<0.05).The level of FGF-21 in the observation group was lower than that in the control group after treatment,and the difference was statistically significant(P<0.05).The IL-6,TNF-α and ASAA of the observation group after treatment were lower than those of the control group,and the differences were statistically significant (P<0.05).After treatment,MDA and LPO in the observation group were lower than those in the control group,and GSH-Px was higher than that in the control group,and the differences were statistically significant (P<0.05).There was no significant difference in the total incidence of adverse reactions between the two groups (P>0.05).Conclusion LRG treatment can improve the BMI and blood glucose level of newly diagnosed obese patients with T2DM,reduce the level of FGF-21,and regulate the indexes related to micro-inflammation and oxidative stress,which is worthy of application.
梁桂敏;苏冬雪;邵 宁;陈 萍;王 莹;马晶. 利拉鲁肽治疗初诊肥胖2 型糖尿病患者的效果[J]. 中国当代医药, 2022, 29(32): 68-71.
LIANG Guimin SU Dongxue SHAO Ning CHEN Ping WANG Ying MA Jing. Effect of Liraglutide on newly diagnosed obese patients with type 2 diabetes mellitus. 中国当代医药, 2022, 29(32): 68-71.